VEGF mitigates bisphosphonate-induced apoptosis and differentiation inhibition of MC3T3-E1 cells

Yao Duan1, Heija Li2, Xiaohong Dong3

  • 1Department of Second Dental Center, Peking University School and Hospital of Stomatology, Beijing 100101, P.R. China.

Insights

Vascular Endothelial Growth Factor (VEGF) protects osteoblasts from bisphosphonate-induced apoptosis and differentiation. VEGF addition enhanced cell viability, mineralization, and alkaline phosphatase activity, while reducing apoptosis in zoledronic acid-treated cells.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Biochemistry

Background:

  • Bisphosphonates (BPs) are commonly used to treat bone diseases.
  • The effects of BPs on osteoblast apoptosis and differentiation require further investigation.
  • Vascular Endothelial Growth Factor (VEGF) is a key regulator of angiogenesis and cellular processes.

Purpose of the Study:

  • To investigate the role of VEGF in bisphosphonate (BP)-induced apoptosis and differentiation of osteoblasts.
  • To elucidate the molecular mechanisms underlying VEGF's effects on osteoblasts treated with zoledronic acid (ZA).

Main Methods:

  • Murine MC3T3-E1 osteoblasts were treated with zoledronic acid (ZA).
  • VEGF expression, cell viability, apoptosis, mineralization, and alkaline phosphatase (ALP) activity were assessed.
  • Western blot analysis was used to evaluate protein expression, including osteogenic genes and the NLRP3/caspase 1/GSDMD pathway.

Main Results:

  • Zoledronic acid (ZA) treatment decreased VEGF expression in MC3T3-E1 cells.
  • VEGF addition enhanced cell viability, promoted mineralization, and increased ALP activity in ZA-treated cells.
  • VEGF attenuated ZA-induced apoptosis and restored the expression of osteogenic genes (osteopontin, osteocalcin, RUNX2).

Conclusions:

  • VEGF plays a protective role against bisphosphonate-induced apoptosis and differentiation in osteoblasts.
  • VEGF attenuates BP-induced apoptosis and differentiation by regulating the NLRP3/caspase 1/GSDMD pathway.
  • VEGF may be a potential therapeutic target for managing bone-related disorders associated with bisphosphonate treatment.

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.2K